ST-Segment Elevation Myocardial Infarction
Conditions
Interventions
Control Group:Starch placebo
Ketotifen Group:Ketotifen 1mg, twice a day
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 or older, any gender; 2. Meeting the diagnostic criteria for STEMI (diagnostic criteria: ischemic chest pain lasting =30 minutes; ST-segment elevation in two or more contiguous leads on ECG or new-onset left bundle branch block; with or without elevated myocardial biomarkers); 3. Diagnosis of STEMI within the past 7 days; 4. Receiving standard treatment as recommended by the "Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction (2019)", including dual antiplatelet therapy, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEI/ARB/ARNI), ß-blockers, statins, and PCI, etc.; 5. Agree to participate and cooperate in this study.
Exclusion criteria
Exclusion criteria: 1.Severe heart failure, such as Killip class IV or LVEF 3× the upper limit of normal; GFR <30 mL/min/1.72 m^2); 5.History of cancer or lymphoproliferative disorders within the past 3 years; 6.Current autoimmune disease, allergic disease, or asthma; 7.Contraindication to ketotifen use, including allergy to the drug or concurrent use of central nervous system depressants; 8.Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiovascular events; | — |
Secondary
| Measure | Time frame |
|---|---|
| high-sensitivity C-reactive protein;Major adverse cardiovascular and cerebrovascular events;Left ventricular ejection fraction;Adverse drug reaction events; | — |
Countries
China
Contacts
Public ContactMing Cui
Peking University Third Hospital
Outcome results
None listed